Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

NCT05565092 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to terminate program.

Conditions

Sickle Cell Disease (SCD)

Interventions

DRUG: ALXN1820

Sponsor

Alexion Pharmaceuticals, Inc.